Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04881448 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 223
- Enrollment target
NCT04881448 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 223 participants.
The verdict
NCT04881448, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 223 participants
- Enrollment target
Study Summary
This study is intended to investigate the usefulness of estimated glomerular filtration rate (eGFR) slopes derived from retrospective routine clinical practice data, compare those retrospective slopes with those generated in a prospective fashion and successively identify rapidly progressing chronic kidney disease (CKD) patients.
Interventions
- DIAGNOSTIC_TEST collection of serum/capillary creatinine values
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04881448
The ClinicalTrials.gov registry entry for NCT04881448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which collection of serum/capillary creatinine values is the first listed.
NCT04881448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04881448 about?
NCT04881448 is a clinical study titled "A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease". This study is intended to investigate the usefulness of estimated glomerular filtration rate (eGFR) slopes derived from retrospective routine clinical practice data, compare those retrospective slopes with those generated in a prospective fashion and successively identify rapidly progressing chronic...
What is the current status of trial NCT04881448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2021-09-16. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT04881448?
The interventions under investigation include: collection of serum/capillary creatinine values (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04881448?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.